IRWD

Ironwood is a one-product company. Management states revenues from the LINZESS/AbbVie collaboration 'constitute a significant portion of our total revenue' and will 'continue to do so for the foreseeable future,' and apraglutide is not yet approved. That single-product dependence is a problem because the base is eroding: revenue fell from $443M (FY2023) to $351M (FY2024) to $296M (FY2025), a -15.7% latest-year drop the 10-K attributes to a $51.1M decline in Ironwood's share of U.S. LINZESS net profits driven by 'decreased net price and inventory channel fluctuations.' Critically, the filing confirms the LINZESS list price was lowered effective January 1, 2026 'in response to evolving health care dynamics' — a self-inflicted forward headwind that makes another year of revenue decline the base case, not the risk case.

The FY2025 headline improvements are real but low-quality on inspection. Operating income rose modestly to $98.5M, but the MD&A credits a $60.6M cut in operating expenses from 2025 restructuring — a shrink-to-profit move, not growth. Net income of $24.0M (+2629% YoY) and diluted EPS of $0.15 (+1400%) look explosive only because they lap a depressed FY2024 base ($0.9M net income); FY2024 itself was distorted by a $43.0M sales-reserve reduction. At $4.33 the stock trades at 28.9x that $0.15 EPS — an expensive multiple for a business whose top line is contracting and whose 2026 price is already cut. The balance sheet also warrants caution: stockholders' equity is negative at -$262M against a -$1.67B accumulated deficit, the residue of a -$1.0B FY2023 loss and prior heavy buybacks.